Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Pierer Mobility (14/06/2024)

16.06.2024

Marinomed: Marinomed Biotech AG expands its license regarding the distribution of Marinomed’s Carragelose products with an existing partner and leading Consumer Health Care market player. The agreement provides for the marketing and distribution of Carragelose products in several EU-countries and some non-EU countries pending any required regulatory approvals. Under the terms of the agreement and depending on the achievement of specified regulatory and commercial targets, Marinomed is eligible to receive milestone payments. “Broadening our license with a leading Consumer Health Company is a huge success and validation of our Carragelose product line”, Andreas Grassauer, CEO of Marinomed, comments. “Expanding to additional countries is another significant step for our business, and we are looking forward to realizing the full potential of our products.”
Marinomed Biotech: weekly performance: 0.38%

Pierer Mobility: In the current financial year, momentum in PIERER Mobility's core motorbike markets in the USA and Europe has slowed significantly. For the 2024 financial year, the Executive Board expects a decline in sales of 10% to 15% for both the motorcycles and bicycle divisions due to the current market developments. In the Motorcycles segment, the Executive Board assumes that the cost savings introduced in the current financial year will be able to compensate for the negative effects of declining sales to such an extent that a balanced to slightly positive EBIT can be generated. The development of existing dealers and the further expansion of the dealer network to support the brand strategy will be key issues in 2024. In the Bicycle division, however, the Executive Board anticipates a significantly negative EBIT of €-110 to €-130 million for the 2024 financial year, which is essentially due to extraordinary impairment and restructuring requirements. The restructuring of the Bicycle division is therefore complete. 
Pierer Mobility: weekly performance: -2.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (14/06/2024)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Pierer Mobility (14/06/2024)


16.06.2024, 2077 Zeichen



Marinomed: Marinomed Biotech AG expands its license regarding the distribution of Marinomed’s Carragelose products with an existing partner and leading Consumer Health Care market player. The agreement provides for the marketing and distribution of Carragelose products in several EU-countries and some non-EU countries pending any required regulatory approvals. Under the terms of the agreement and depending on the achievement of specified regulatory and commercial targets, Marinomed is eligible to receive milestone payments. “Broadening our license with a leading Consumer Health Company is a huge success and validation of our Carragelose product line”, Andreas Grassauer, CEO of Marinomed, comments. “Expanding to additional countries is another significant step for our business, and we are looking forward to realizing the full potential of our products.”
Marinomed Biotech: weekly performance: 0.38%

Pierer Mobility: In the current financial year, momentum in PIERER Mobility's core motorbike markets in the USA and Europe has slowed significantly. For the 2024 financial year, the Executive Board expects a decline in sales of 10% to 15% for both the motorcycles and bicycle divisions due to the current market developments. In the Motorcycles segment, the Executive Board assumes that the cost savings introduced in the current financial year will be able to compensate for the negative effects of declining sales to such an extent that a balanced to slightly positive EBIT can be generated. The development of existing dealers and the further expansion of the dealer network to support the brand strategy will be key issues in 2024. In the Bicycle division, however, the Executive Board anticipates a significantly negative EBIT of €-110 to €-130 million for the 2024 financial year, which is essentially due to extraordinary impairment and restructuring requirements. The restructuring of the Bicycle division is therefore complete. 
Pierer Mobility: weekly performance: -2.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (14/06/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsenradio Live-Blick, Mi. 24.7.24: DAX startet leichter, Deutsche Bank abverkauft, Sartorius-Comeback, Immofinanz/CPI-Fusion?




 

Bildnachweis

Aktien auf dem Radar:Warimpex, CA Immo, FACC, Austriacard Holdings AG, Addiko Bank, Polytec Group, Telekom Austria, Erste Group, Immofinanz, Rosenbauer, VIG, Gurktaler AG Stamm, Gurktaler AG VZ, Marinomed Biotech, S Immo, Wiener Privatbank, Oberbank AG Stamm, Agrana, Amag, EVN, Flughafen Wien, Österreichische Post, Uniqa, Wienerberger, SAP, Sartorius, RWE, Vonovia SE, Siemens Energy, Siemens Healthineers, DAIMLER TRUCK HLD....


Random Partner

Erste Asset Management
Die Erste Asset Management versteht sich als internationaler Vermögensverwalter und Asset Manager mit einer starken Position in Zentral- und Osteuropa. Hinter der Erste Asset Management steht die Finanzkraft der Erste Group Bank AG. Den Kunden wird ein breit gefächertes Spektrum an Investmentfonds und Vermögensverwaltungslösungen geboten.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten